Navigation Links
Intercept Pharmaceuticals and Servier Announce Agreement for Intercept's TGR5 Research Program in Type 2 Diabetes
Date:8/9/2011

NEW YORK, and NEUILLY, France, Aug. 9, 2011 /PRNewswire/ -- Intercept Pharmaceuticals, Inc. (Intercept) and Les Laboratoires Servier (Servier) today announced that they have entered into a worldwide ex-U.S. and Japan agreement for the discovery and development of novel TGR5 agonists for the treatment of type 2 diabetes and other metabolic indications. The collaboration will leverage Intercept's drug discovery platform based on its proprietary bile acid analog chemistry and expertise targeting TGR5 and other bile receptors.

Under the terms of the agreement, Intercept will receive up to $163 million in total upfront, research support and milestone payments, as well as royalties on sales, based on the successful outcome of the collaboration. Intercept and Servier will jointly support the discovery effort, while Servier alone will be responsible for all costs associated with the global development, regulatory approval and commercialization of any compound selected as a lead candidate by the parties. Intercept retains all rights in the U.S. and Japan.

"This agreement provides important validation of our approach to targeting TGR5," said Mark Pruzanski, MD, Intercept's President and Chief Executive Officer. "Type 2 diabetes and associated metabolic disorders have reached epidemic proportions globally and there is a critical need for novel effective and safe drugs. Intercept is uniquely positioned to exploit the therapeutic potential of rationally modified bile acids, which play a central role in the maintenance of metabolic homeostasis.  I am thrilled to enter this agreement with Servier given the company's commitment to research and expertise in this therapeutic area."

"We are very happy to enter into this collaboration with Intercept which will allow us to further expand our diabetes and metabolic disease franchise," stated Emmanuel Canet, MD, PhD, Head of Servier R&D. "TGR5 is a target of great interest with its effects on GLP-1 that complement those of other classes of marketed diabetes drugs."

About TGR5

TGR5 (GPR131) is a cell-surface G protein coupled receptor that is regulated by bile acids. Bile acids are known to be key regulators of lipid, glucose and overall energy metabolism. This receptor has been shown to be a key regulator of energy homeostasis through induction of the incretin GLP-1 in the intestine with resulting insulin sensitizing effects, as well as through activation of metabolic pathways in brown adipose tissue and skeletal muscle that drive energy expenditure and resulting resistance to weight gain. TGR5 is also involved in the modulation of cytokine production by immune cells, potentially playing a role in the control of inflammation.

About Intercept Pharmaceuticals

Intercept is a biotechnology company focused on discovering and developing small molecule drugs for the treatment of chronic liver and metabolic diseases.  The company's most advanced programs are focused on the development of modified bile acids that are selective for FXR, a nuclear receptor, and TGR5. Bile acid signaling through these receptors regulates key aspects of lipid, glucose and overall energy metabolism, while also serving to maintain the functional integrity of the liver, intestine and kidneys, organs that are exposed to bile acid flux. For more information about Intercept, please go to www.interceptpharma.com and for information about Intercept's lead investor, Genextra S.p.A., please go to www.genextra.it. CONTACT: Mark Pruzanski, M.D. or Barbara Duncan, both of Intercept Pharmaceuticals, +1-646-747-1000.

About Servier

Servier is the leading independent pharmaceutical company in France with sales worldwide reaching EUR3.7 billion in 2010. The Servier Research Group is established in 140 countries with its main therapeutic products treating type II diabetes, cardiovascular diseases, CNS disorders, oncology and rheumatological diseases.  More than 25% of Servier's turnover is invested in research and development (R&D). Servier has 20,000 employees worldwide, including nearly 3,000 in R&D. For further information, please go to www.servier.com.


'/>"/>
SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis
2. Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease
3. Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals Obeticholic Acid (INT-747) in NASH
4. Intercept Pharmaceuticals to Collaborate With NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH)
5. Intercept Pharmaceuticals Raises $25 Million Series B Financing
6. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
7. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
8. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
9. K-V Pharmaceutical Company Announces the Completion of the Sale of Nesher Pharmaceuticals, Inc. its Generic Pharmaceutical Business
10. Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results
11. Auxilium Pharmaceuticals, Inc. Announces Promotion of Dr. James P. Tursi to Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ReportsnReports.com adds "Pulmonary Arterial ... report that provides an overview of the PAH ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Pulmonary Arterial ...
(Date:4/29/2016)... 29, 2016 ... Sanofi, leader mondial et ... résultats pour le premier trimestre 2016. ... Contamine, commente les résultats du premier ... pour le reste de l,année. ...
(Date:4/29/2016)... April 29, 2016 Automation is ... laboratory due to the growing demands for productivity in ... contemporary automated systems are already adept of a wide ... tedious and manual labor. Instrumentation continues to evolve, and ... conceivable just a few years ago. Originally used mostly ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... enterprise focused entirely on patients with cancer, today announced that Lynne Malestic, RN, ... the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors nurses ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, ... animal line of probiotics, Petbiotics ™, as they fondly call them. As ... rescue groups networking for their non-profit organizations. Animal rescues across the nation face ...
(Date:4/29/2016)... ... April 29, 2016 , ... Coalition ... muscular dystrophy, and funding for Duchenne research, participated in the April 25 U.S. ... Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the Marriott Conference Center in ...
(Date:4/29/2016)... ... 29, 2016 , ... The Society for Assisted Reproductive Technology ... required to report in vitro fertilization (IVF) delivery rates to both ... of assisted reproductive technologies in the United States. , This year, SART’s ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... The ... the workforce is aging – meaning that there is an urgent need for highly ... and interactive training solution, delivering a multi-pronged approach to train and retain care managers, ...
Breaking Medicine News(10 mins):